SCHEMBL7166244

SCHEMBL7166244

Cn1cncc1C(O)Cc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 8/20 0.44
TRPA1 O75762 2/20 0.43
TDO2 P48775 1/20 0.43
CYP2D6 P10635 1/20 0.39
HPGDS O60760 1/20 0.38
MAPT P10636 1/20 0.38
SLC6A2 P23975 3/20 0.37
TAAR1 Q96RJ0 2/20 0.37
SLC6A4 P31645 2/20 0.37
SLC6A3 Q01959 2/20 0.37
MAOA P21397 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CYP2A6 P11509 1/20 0.37
ADORA2A P29274 1/20 0.37
ADORA1 P30542 1/20 0.37
CYP11B1 P15538 2/20 0.37
CYP11B2 P19099 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7567362 0.85 IDO1 (0.42) IDO1CYP2D6SLC6A2SLC6A4SLC6A3
SCHEMBL7572062 0.82 CYP11B1 (0.47) CYP11B1CYP11B2
SCHEMBL7166927 0.81 CYP2D6 (0.46) CYP2D6HPGDSSLC6A2TAAR1SLC6A4
SCHEMBL10790711 0.78 CYP11B1 (0.54) IDO1TRPA1TDO2CYP2D6HPGDS
Hydrochloric Acid SCHEMBL7137318 0.76 SLC6A2 (0.36) TRPA1CYP2D6HPGDSSLC6A2SLC6A4
SCHEMBL7571137 0.75 KDM4E (0.49) IDO1TDO2CYP2D6HPGDS
SCHEMBL10789640 0.74 CYP3A4 (0.47) IDO1CYP2D6HPGDSCYP11B1CYP11B2
SCHEMBL22776004 0.73
SCHEMBL8128480 0.72 FNTA (0.42) IDO1CYP11B1CYP11B2
SCHEMBL18137400 0.72 IDO1 (0.49) IDO1TDO2CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1276726-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS Abbott Laboratories (US) 2003-01-22 EP disclosed
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors ABBOTT LABORATORIES 2002-02-14 US disclosed
WO-2001081316-A2 SUBSTITUTED PHENYL FARNESYLTRANSFERASE INHIBITORS ABBOTT LABORATORIES (US) 2001-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019527-A1 Substituted phenyl farnesyltransferase inhibitors FNTA, FNTB, SLC10A1 IDO1 3762/4885TRPA1 4474/4885TDO2 4115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.